ConjuChem retains Bloom Burton

A committee of independent directors of insolvent ConjuChem Biotechnologies (TSX:CJB) has retained health care investment bankers Bloom Burton & Co. “to solicit and evaluate options for the company with a view to maximize value for shareholders and other stakeholders.”

ConjuChem received court protection under the Companies’ Creditors Arrangement Act (Canada) on Feb. 26.  The TSX plans to delist ConjuChem at the close on April 6 for failure to meet continued listing requirements.  The stock remains suspended from trading.